Special Issue "Current Therapies for Endometriosis, Adenomyosis and Endometrial Cancer"

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: 30 September 2023 | Viewed by 427

Special Issue Editors

Dr. Ambrogio Pietro Londero
E-Mail Website
Guest Editor
Research Associate in the Academic Unit of Obstetrics and Gynaecology, Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Infant Health, University of Genoa, Genova, Italy
Interests: endometrial cancer
Academic Unit of Obstetrics and Gynecology, Maternal and Child Health (DiNOGMI), IRCCS Ospedale Policlinico San Martino, Genova, Italy
Interests: gynecological ultrasound; endometriosis and pelvic pain; oncological gynecology
Special Issues, Collections and Topics in MDPI journals
Clinic of Obstetrics and Gynecology, Azienda Ospedaliera Universitaria San Martino di Genova, Genova, Italy
Interests: menopause; contraception; endometriosis; pelvic pain; gynecological endocrinology; biological rhytms; gynecological oncology

Special Issue Information

Dear Colleagues,

Endometriosis, adenomyosis, and endometrial cancer are three gynecological conditions with varying options for treatment. Endometriosis constitutes a complex disease whose etiology is not fully understood. Reflecting this, therapies to address this condition are mainly symptomatic, aimed at pain control and improving fertility through medical treatments, surgery, and medically assisted procreation. Adenomyosis is another estrogen-dependent condition that can cause pain, heavy bleeding, and infertility. While drug therapies can effectively relieve symptoms, the respite is temporary. Adenomyosis can also be associated with other conditions like endometriosis, and in rare cases, it can lead to adenocarcinomas, making diagnosis and treatment complicated. Conversely, there have been promising developments in identifying novel diagnostic markers and therapeutic targets of endometrial cancer. Potential therapeutic strategies for endometrial cancer include targeting specific pathways, such as mTOR or CDK4/6, and analyzing long non-coding RNA. Radiomics features and models have also been validated to differentiate endometrial cancer risk groups. However, a better understanding of these conditions' mechanisms is still needed to develop therapies with curative or preventive application. New developments for the treatment all three of the discussed pathologies include both hormonal and non-hormonal treatments. This Special Volume aims to discuss the merits of this area's current and future therapeutic lines.

Dr. Ambrogio Pietro Londero
Dr. Anjeza Xholli
Dr. Angelo Cagnacci
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • endometriosis
  • adenomyosis
  • endometrial cancer
  • hormonal therapy
  • non-hormonal therapy
  • pain management
  • fertility preservation
  • complementary/alternative medicine
  • radiation therapy
  • chemotherapy
  • immunotherapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Clinical Efficacy, Pharmacokinetics, and Safety of the Available Medical Options in the Treatment of Endometriosis-Related Pelvic Pain: A Scoping Review
Pharmaceuticals 2023, 16(9), 1315; https://doi.org/10.3390/ph16091315 - 18 Sep 2023
Viewed by 255
Background: In this scoping review, we sought to identify published studies evaluating the drugs currently used in the treatment of endometriosis-related pelvic pain, with reflection on their chemical properties, pharmacokinetics, safety profile, and clinical efficacy. Methods: A literature search was conducted with the [...] Read more.
Background: In this scoping review, we sought to identify published studies evaluating the drugs currently used in the treatment of endometriosis-related pelvic pain, with reflection on their chemical properties, pharmacokinetics, safety profile, and clinical efficacy. Methods: A literature search was conducted with the use of the PubMed and EMBASE electronic databases, focusing on identifying articles published in English between January 1990 and 2023. Results: Based on the included studies, current therapy options for the treatment of endometriosis-related pain identified and reviewed in this article were: (1) non-steroidal anti-inflammatory drugs; (2) combined oral contraceptive (COCs); (3) progestins; (4) gonadotropin-releasing hormone agonists and antagonists; (5) aromatase inhibitors (AIs); (6) selective estrogen and progesterone receptor modulators; and (7) levonorgestrel-intrauterine device. Conclusions: Based on the published evidence, clinicians should consider NSAIDs, COCs, and progestins as the first-line medical therapies. Compared with second-line options, such as GnRH agonists/antagonists or AIs, the abovementioned first-line options are well tolerated, efficacious, and exhibit lower overall price. Future research priorities should be to identify novel target therapies and to evaluate the effects of available drugs through different routes of administration. Full article
Show Figures

Figure 1

Back to TopTop